Acknowledgements The insights contained within this publication were generated in part by funding from the Gates Foundation to M.K.OB
Obesity worsens depression, anxiety, and self-esteem
Both medications require specialist precision and structured follow-up to manage potential gastrointestinal side effects and ensure patient safety
A higher count gives better chances, for sure [1]
Retatrutide, a GIP/GLP-1/Glucagon receptor agonist (GGG tri-agonist) in development by Eli Lilly and Company, isnt on the market yet
These can include: Hypersensitivity or allergic reactions Nausea, vomiting, or diarrhea Headaches or dizziness Joint pain or stiffness A flushing sensation after injection It is important to note that these risks are rare and usually mild